The Mounjaro injection: facts, not myths

The biggest myth: Mounjaro is just a diet jab you can pick up anywhere

The phrase that circulates most on social media is that these injections are widely available, easy to obtain and essentially self-managed. That is not accurate. Mounjaro (tirzepatide) is a Prescription-Only Medicine under UK law, which means it can only be dispensed after a registered prescriber has assessed your medical history, current conditions and any medicines you take. No pharmacy (online or otherwise) can legally supply it without that clinical step.

The MHRA has flagged this explicitly in its public guidance on GLP-1 medicines, and has seized large quantities of fake weight-loss pens sold through social media channels. Counterfeit pens have been found to contain incorrect substances; some hospitalisations have followed. If you are looking at Mounjaro from a seller who does not ask for a consultation, that is the single biggest red flag you can encounter. You can check whether any online pharmacy is legitimate by searching the GPhC pharmacy register before handing over any personal or payment details.

The injection itself, once properly prescribed, is genuinely straightforward. A thin needle is used subcutaneously (into the fat layer of the abdomen, thigh or upper arm) and the pen mechanism makes the process simple enough that most people feel comfortable within the first week.

How tirzepatide works differently from other weight-loss injections

Most GLP-1 medicines on the UK market act on a single receptor pathway. Tirzepatide does something distinct: it activates both the GLP-1 receptor and the GIP receptor simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone involved in fat storage and insulin release. Activating both pathways together appears to produce stronger appetite suppression and greater average weight loss than single-agonist medicines in head-to-head trials.

The practical effect for most people is a significant reduction in hunger between meals, slower gastric emptying (food moves through the stomach more gradually, prolonging fullness), and a shift in food preferences. These are biological changes, not willpower changes. The NHS tirzepatide medicines page explains the mechanism in patient-level terms if you want a plain-language reference.

It is worth reading about how semaglutide compares if you are weighing up your options. Our tirzepatide overview covers the clinical evidence in more depth, including the SURMOUNT-5 head-to-head data against semaglutide 2.4 mg.

What the Mounjaro injection schedule looks like in practice

Treatment starts at 2.5 mg, a dose that exists primarily to let your system adjust, particularly your digestive system. Most of the gastrointestinal side effects people report (nausea, loose stools, indigestion) are dose-related and tend to settle after the first few weeks at each level. Rushing through the titration schedule is one of the most common reasons for dropping out early.

From 2.5 mg, your prescriber increases the dose roughly every four weeks, moving through 5 mg, where many people notice appetite suppression becoming more consistent, then 7.5 mg, 10 mg, 12.5 mg and up to 15 mg depending on how you are tolerating it and what progress looks like. NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment should be reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose.

If you want detail on what the 2.5 mg starting pen involves specifically, the 2.5 mg Mounjaro page covers it. For context on how pricing fits into the decision, our Mounjaro cost guide walks through what is typically included in a legitimate private prescription.

At nume (at nume) once a prescriber approves a prescription, the pen is dispatched the same day (for orders placed by 12pm, Monday to Friday) and delivered by DPD the next working day in plain, unbranded packaging. What arrives is the KwikPen itself, with dosing information inside, discreet, tracked and temperature-safe for transit.

Who this injection is and is not suitable for

The licensed criteria for Mounjaro, which you can read about in full on our dedicated treatment page, cover adults aged 18 and over with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not determine approval, your prescriber reviews the full picture.

Mounjaro is not suitable during pregnancy, while breastfeeding or if you are trying to conceive. It is not licensed for under-18s. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or with a history of pancreatitis, needs to discuss this with a prescriber before starting. Women taking oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, as absorption of the pill may be affected, this is specific to tirzepatide and is worth knowing ahead of any consultation.

If you are unsure whether you are a candidate, you can find out more about e-Mounjaro and how our online prescribing process works before the free consultation at nume is where that question gets answered properly. A GPhC-registered Independent Prescriber reads every set of answers the same day, not automated scoring, a real clinician.